Omeros’ Yartemlea launch is converting exclusive TA-TMA positioning into 97.2% gross-margin growth, with reimbursement catalysts supporting substantial five-year upside.
Overview
Omeros Corporation is a commercial-stage biopharmaceutical company whose investment profile changed materially after FDA approval of Yartemlea in late December 2025. Yartemlea is the first and only approved treatment for highly lethal TA-TMA, giving Omeros a differentiated position in an ultra-orphan market with an estimated 2,000–3,000 severe U.S. patients and potential U.S. revenue of $500–750 million. **Commercial traction is emerging rapidly:** Q2 2026 net product sales reached $28.529 million, up 188% sequentially from $9.893 million, versus zero in Q2 2025, while gross margin was 97.2% and adjusted EPS was $0.02. The company reached operating breakeven and expects company-wide positive operating cash flow by mid-2027. **The central catalyst is reimbursement-enabled adoption:** permanent J-code status is active and NTAP reimbursement of up to $287,079 begins October 1, 2026. The $2.1 billion Novo Nordisk deal adds milestone and royalty support for Zaltenibart and reduces financing risk. Risks include a negative European CHMP opinion, dependence on a concentrated transplant-center customer base, off-label competition, and historical execution problems. At $13.59, the report’s probability-weighted five-year value is $40.50.